Onecyte Biotechnologies, Inc.
Watertown, MA
- UEI
- ERE5JFD78JB9
- CAGE
- 82HH8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 199 Dexter Ave #14, Watertown, MA 02472, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Proteios Technology, Inc. | Issaquah, WA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Nectagen Inc. | Lawrence, KS | 325414 Biological Product (except Diagnostic) Manufacturing |
| Flexomics LLC | Waltham, MA | — |
| Enrich Biosystems Inc. | Branford, CT | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Cytorum, Inc. | Santa Clara, CA | — |
About the company
Onecyte Biotechnologies, Inc., doing business as Onecyte Biotechnologies Inc., is a for-profit corporate entity that provides innovative biotechnology solutions. It has developed a proprietary single-cell proteomics platform technology aimed at accelerating the manufacturing and transition of new biologics, such as therapeutics and vaccines, from the laboratory to commercial-scale production.
Through several federal grant awards totaling over $5.5 million, Onecyte has been funded to advance its single-cell analytics capabilities for accelerating biologics manufacturing. A $988,939 NSF Cooperative Agreement under the Technology, Innovation, and Partnerships program supported developing a high-throughput microfluidic platform to reduce cell line development time from 6 months to 1 day. A $4.3 million NIH/NCATS Project Grant enabled expanding single-cell assays to screen for critical product quality attributes affecting drug safety, efficacy, manufacturability, and yield. It also funded automating data analytics and transitioning to commercial processes. An earlier $256,000 NSF SBIR Phase I grant focused on applying the platform to accelerate COVID-19 vaccine and therapeutic development. Onecyte collaborates with biopharma industry partners, leveraging its cutting-edge single-cell technologies to shorten timelines and reduce costs for novel preventative and therapeutic medicines.
Quick answers
Is Onecyte Biotechnologies, Inc. registered in SAM.gov?
Yes. Onecyte Biotechnologies, Inc.'s SAM.gov registration is active through April 14, 2027.
What is Onecyte Biotechnologies, Inc.'s most recent federal award?
Onecyte Biotechnologies, Inc.'s most recent federal grant award is Sbir phase II: a high throughput microfluidic platform to accelerate biomanufacturing transitions in biologics… (2309447), from National Science Foundation, on September 15, 2023.
On GovTribe
See Onecyte Biotechnologies, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors